Overview

Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy

Status:
Not yet recruiting
Trial end date:
2023-07-07
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the safety and tolerability of pozelimab and cemdisiran combination therapy in participants with PNH who switch from eculizumab therapy The secondary objectives of the study are: - To evaluate the effect of the combination treatment on the following parameters of intravascular hemolysis: lactate dehydrogenase (LDH) control, breakthrough hemolysis, and inhibition of CH50 - To evaluate the effect of the combination treatment on the stability of LDH during the transition period from eculizumab monotherapy to combination with pozelimab and cemdisiran - To evaluate the effect of the combination treatment on red blood cell (RBC) transfusion requirements - To evaluate the effect of the combination treatment on hemoglobin levels - To evaluate the effect of the combination treatment on clinical outcome assessments (COAs) measuring fatigue and health related quality of life (HRQoL) - To assess the concentrations of total pozelimab and eculizumab in serum; and total cemdisiran and C5 protein in plasma - To assess the immunogenicity of pozelimab and cemdisiran - To assess safety after dose intensification - To evaluate the long-term safety and efficacy of the combination treatment in an optional open-label extension period (OLEP)
Phase:
Phase 2
Details
Lead Sponsor:
Regeneron Pharmaceuticals